<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01875354</url>
  </required_header>
  <id_info>
    <org_study_id>13-PHX-01-NU-02</org_study_id>
    <nct_id>NCT01875354</nct_id>
  </id_info>
  <brief_title>A Prospective Study Investigating the Effects of a Novel Weight Management Program</brief_title>
  <official_title>A Prospective, Randomized, Blinded, Controlled Study Investigating the Effects of a Novel Body Weight Management Program Over 90-days and Weight Maintenance at One Year.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmanex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Utah State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmanex</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of a weight management program
      composed of dietary supplements and a reduced calorie eating program.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the effect of a novel weight management program on body fat mass over 90 days.</measure>
    <time_frame>Days 0 and 90</time_frame>
    <description>Evaluate changes in body measurements (weight and BMI; arm, waist, hip, thigh, claf, and ankle circumferences) and body composition (fat mass, fat free mass, % body fat) by Dual Energy X-ray Absorptiometry (DEXA) scanner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the safety of novel weight management program (CBC, Comp. metabolic, lipid panel, heart rate, blood pressure and adverse events)</measure>
    <time_frame>Throughout 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate changes in body measurements (weight and BMI; arm, waist, hip, thigh, claf, and ankle circumferences) and body composition (fat mass, fat free mass, % body fat) by Dual Energy X-ray Absorptiometry (DEXA) scanner.</measure>
    <time_frame>throughout 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine subjective measurements of hunger and appetite from standardized questionnaires (IWQOL Hunger/Appetite and overall wellbeing)</measure>
    <time_frame>Throughout 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine skin carotenoid (Biophotonic Scanner) measurement changes.</measure>
    <time_frame>Throughout 1 year</time_frame>
    <description>Biophotonic Scanner utilizes raman spectroscopy to determine skin carotenoid concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in metabolism and appetite hormone levels from the baseline visit to day 90.</measure>
    <time_frame>Days 0 and 90</time_frame>
    <description>Leptin, Insulin, Adiponectin, Pancreatic Polypeptide, gLP1, C-peptide, Glucagon, Resistin and HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in inflammatory markers from the baseline visit to day 90.</measure>
    <time_frame>Days 0 and 90</time_frame>
    <description>hsCRP, IL-6 and TNF Receptors 60 and 80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in gene expression from the baseline visit to day 90.</measure>
    <time_frame>Day 0 and 90</time_frame>
    <description>Full gene arrays will be made on peripheral blood mononuclear cells. The gene expression changes will be made at baseline and day 90. There will also be a comparison back to proteins (i.e. hormones and inflammatory markers).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate resting energy expenditure and substrate utilization from baseline to days 90, 180, and 365.</measure>
    <time_frame>Days 0, 90, 80, and 365</time_frame>
    <description>Resting metabolic rate (RMR)and substrate utilization (R-values to determine wheather subjects are utilizing more fats or carbohydrates to meet energy demands) will be measured by CPET Quark.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Placebo and Low Fat Eating Plan</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)
The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary Supplements and TR90 Eating Plan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)
Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Supplements and TR90 Eating Plan</intervention_name>
    <description>Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates</description>
    <arm_group_label>Dietary Supplements and TR90 Eating Plan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo and Low Fat Eating Plan</intervention_name>
    <arm_group_label>Placebo and Low Fat Eating Plan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 18-65 years of age at the time of informed consent

          2. The ability to read, speak and understand the English language in order to complete
             the required paper informed consent, assessments and diary

          3. Access to email and to a digital camera or camera phone

          4. Willing and able to provide written informed consent

          5. Willing and able to comply with the study restrictions, procedures and assessments and
             attend regularly scheduled clinic visits

          6. Willing and able to accommodate being contacted by the study staff for telephone call
             visits, follow-up contacts, and study visit reminders

          7. BMI is equal to or greater than 25 and less than or equal to 40 kg/m2

          8. Use of effective method of contraception by females of childbearing potential 30-days
             before the screening visit and agree to continue to practice that acceptable method of
             contraception for the duration of her participation in the study

          9. A resting normotensive blood pressure, as defined as a systolic blood pressure between
             150-90 mmHg and a diastolic blood pressure of between 95-50 mmHg, at screening visit
             1(A)

         10. Willing to fast for at least 8 hours prior to the study procedures being performed
             that require fasting measurements

         11. Willing and able to follow eating program and able to consume the study supplied
             Supplements, Placebos and shakes (which include whey and/or egg protein) on a daily
             basis. Subjects that are lactose intolerant will be considered ineligible

         12. Only one member per household eligible to participate in the study

        Exclusion Criteria:

          1. A subject that has any Axis I Psychiatric disorders according to the DSM-IV criteria
             that would prevent the subject from being able to comply with study requirements
             and/or taking anti-psychotic medication

          2. Diagnosed with insomnia and is chronically using prescribed or OTC insomnia
             medications

          3. A self-reported chronic condition that may affect subject safety

          4. An HbA1c of greater than or equal to 7.0%

          5. Renal insufficiency as defined by a laboratory Glomerular Filtration Rate of less than
             50 mL/min/1.73 m2

          6. Chronically using glucocorticoid steroids

          7. Currently pregnant, planning to become pregnant during the course of the study or is
             breastfeeding

          8. Use of antihypertensive medication(s) for less than 90 days prior to screening

          9. Diagnosed with any thyroid disorder or has a clinically significant out of range
             laboratory value (i.e. TSH, T3 Free, and/or T4 Free) value measured at screening

         10. Known allergy or intolerance to any of the ingredients contained in the Novel
             Supplements, placebos or shakes (cow milk proteins)

         11. Planned surgical procedure during the 365 day course of the study

         12. Currently participating in another clinical research study or have done so within 30
             days prior to the screening visit

         13. Diagnosis of milk or egg intolerance

         14. Participating in another weight loss program or using another weight loss product.
             Subjects may enroll if they are willing to stop the weight loss program they are
             currently on and/or washout of the product they are using. The appropriate washout
             will be reviewed with the investigator or medically qualified designee on a case by
             case basis

         15. Fasting LDL-C greater than 190 mg/dL or triglycerides greater than 400 mg/dL.

         16. Unwilling to discontinue consumption of green or black tea or green or black tea
             extracts beginning at the screening visit and after signing of the informed consent

         17. Unwilling to discontinue use of over-the-counter and/or prescribed vitamin supplements
             except for: multivitamins, calcium, fish oil, vitamin C, vitamin D, vitamin E, zinc or
             iron

         18. Plans to have plastic or reconstructive surgery or any other procedure that, in the
             opinion of the investigator, could influence body composition, at any time during the
             year long study

         19. Unable to lay supine for at least 30 minutes

         20. Cognitive impairment that would limit ability to understand or follow diet
             instructions and/or comply with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lefevre, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Utah State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Utah State University</name>
      <address>
        <city>Logan</city>
        <state>Utah</state>
        <zip>84322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

